+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy



Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy



Calcified Tissue International 83(2): 85-92



Treatment of postmenopausal osteoporosis (PMO) is based primarily on antiresorptive agents, including hormone replacement therapy (HT). To evaluate whether anabolic therapy together with HT provides additional benefits in the treatment of PMO, we evaluated the effects of parathyroid hormone (PTH) 1-84 in postmenopausal women with low bone mineral density (BMD) who were receiving chronic (> or =6 months) HT. Subjects were randomized to receive 100 microg PTH(1-84) or placebo injections daily for 24 months (n = 90/group). The primary efficacy outcome was change from baseline in lumbar spine BMD. Secondary end points included changes in hip and distal radius BMD, bone turnover markers, and fracture incidence. The study was terminated early following recommendations regarding HT for PMO. At 18 months, the mean increase in lumbar spine BMD was 7.9% for PTH(1-84) subjects vs. 1.5% for those receiving HT alone; between-group differences were significant at 6 months and persisted throughout the study. Lumbar spine BMD increased in 94% of women receiving PTH(1-84) compared to 59% for HT alone. Femoral neck BMD and bone turnover markers were significantly higher in PTH(1-84)-treated subjects, but the changes in total hip and distal radius BMD were not significant. PTH(1-84) treatment was generally well-tolerated, with hypercalciuria, hypercalcemia, nausea, vomiting, and dizziness reported more frequently in the HT + PTH(1-84) group. In conclusion, addition of PTH(1-84) to stable HT produced marked increases in lumbar spine BMD and may represent an additional approach to the treatment of PMO women receiving HT.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054864535

Download citation: RISBibTeXText

PMID: 18626566

DOI: 10.1007/s00223-008-9152-3


Related references

Bone mass continues to increase after parathyroid hormone treatment is stopped in osteoporotic women on low dose corticosteroids and hormone replacement therapy. Arthritis & Rheumatism 41(9 Suppl. ): S137, Sept, 1998

Markers of bone turnover in postmenopausal women receiving hormone replacement therapy. Clinical Chemistry and Laboratory Medicine 39(5): 414-417, 2001

A comparison of circulating hormone levels in postmenopausal women receiving hormone replacement therapy. American Journal of Obstetrics & Gynecology 167(2): 459-460, 1992

Pulse amplitude and frequency modulation of parathyroid hormone in early postmenopausal women before and on hormone replacement therapy. Journal of Clinical Endocrinology and Metabolism 78(1): 48-52, 1994

Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women. European Journal Of Obstetrics & Gynecology & Reproductive Biology. 47(1): 53-57, 1992

A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. Journal of Clinical Endocrinology and Metabolism 82(2): 620-628, 1997

Two polymorphisms in the vitamin D receptor gene--association with bone mass and 5-year change in bone mass with or without hormone-replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research 17(8): 1535-1544, 2002

Changes in pituitary gonadotropins according to body mass index and adipose tissue distribution, in postmenopausal women receiving different types of hormone replacement therapy. Ginecologia Y Obstetricia de Mexico 68: 212-217, 2000

Relationship between circulating estradiol levels, body mass index, and breakthrough bleeding in postmenopausal women receiving hormone replacement therapy. Menopause 5(1): 24-27, 1998

Alendronate use in postmenopausal women with low bone mass Combination with, comparison to, and use after discontinuation of hormone replacement therapy. Arthritis & Rheumatism 42(9 Suppl. ): S291, Sept, 1999

Hormone replacement therapy is more effective on bone mass in late postmenopausal Japanese women than in early ones. Journal of Bone & Mineral Research 15(Suppl 1): S555, 2000

Fatty acid composition of serum phospholipid of premenopausal women and postmenopausal women receiving and not receiving hormone replacement therapy. Menopause 10(5): 448-455, 2003

A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study. Journal of Bone and Mineral Research 28(11): 2266-2276, 2014

Polymorphisms in the CYP19 and AR genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study. Calcified Tissue International 74(1): 25-34, 2003

Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy: a randomized, double-blind, placebo-controlled trial. Archives of Internal Medicine 162(12): 1409-1415, 2002